Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Ordinary Shares, par value GBP 0.003 per share
-
Shares outstanding
-
792,553,191
-
Total 13F shares
-
73,625,094
-
Share change
-
-15,094,048
-
Total reported value
-
$82,466,840
-
Put/Call ratio
-
66%
-
Price per share
-
$1.12
-
Number of holders
-
58
-
Value change
-
-$16,891,885
-
Number of buys
-
29
-
Number of sells
-
29
Institutional Holders of Mereo BioPharma Group plc - Ordinary Shares, par value GBP 0.003 per share (MREO) as of Q2 2022
As of 30 Jun 2022,
Mereo BioPharma Group plc - Ordinary Shares, par value GBP 0.003 per share (MREO) was held by
58 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
73,625,094 shares.
The largest 10 holders included
Rubric Capital Management LP, Point72 Asset Management, L.P., SUVRETTA CAPITAL MANAGEMENT, LLC, ORBIMED ADVISORS LLC, Rock Springs Capital Management LP, Clearline Capital LP, CITADEL ADVISORS LLC, ORBIMED ADVISORS LLC, BOXER CAPITAL, LLC, and ALKEON CAPITAL MANAGEMENT LLC.
This page lists
59
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.